The in vitro activity of cefotetan, a new cephamycin, was compared with the activities of cefoxitin, cefuroxime, moxalactam, ceftazidime, and piperacillin against 273 recent clinical isolates. The minimum inhibitory concentrations of cefotetan for 90% of Enterobacteriaceae, Haemophilus influenzae, and Neisseria gonorrhoeae were between 0.12 and 2 jig/ml; for 90% 
methylene) -1,3 -dithietan -2 -yl -]carboxyamido -7 -methoxy -3 -(1 -methyltetrazol -5 -yl)thiomethyl -3 -cephem -4 -carboxylate. It has high activity against a broad spectrum of bacteria (8) . In the current study the activities of cefotetan and other r3-lactam antibiotics were compared in vitro against a wide range of recent clinical isolates and also against characterized strains producing ,B-lactamase. The serum protein binding of cefotetan was determined, and the effect of serum upon the activity was studied. MATERIALS Tables 1 to 3 according to classification and number.) The remaining six were wellcharacterized P-lactamase-producing strains donated by Glaxo Research Laboratories.
The antibiotics, of known potency, were obtained from the following sources: cefotetan (disodium) from Imperial Chemical Industries, Macclesfield An increase in inoculum to 106 CFU when testing the Enterobacteriaceae resulted in at most a twofold decrease in susceptibility to cefotetan, moxalactam, cefuroxime, ceftazidime, and cefoxitin, but a greater effect was noted with the P-lactamase-producing strains when tested against piperacillin.
Cefotetan displayed poor activity against Pseudomonas aeruginosa, the mode MIC being 32 jxg/ml. Ceftazidime was the most active agent tested, the strains being about 32-fold more susceptible to it than to cefotetan. Cefoxitin had no activity against P. aeruginosa.
Cefotetan and cefoxitin were considerably less active than cefuroxime, moxalactam, or ceftazidime against H. influenzae. The P-lactamase-producing strains were as susceptible to cefotetan as the non-p-lactamase producers.
Against B. fragilis, cefotetan, ceftazidime, and cefuroxime displayed less activity than moxalactam and cefoxitin. The mode MIC for these strains to cefotetan was 4 ,ug/ml, but 6 of the 27 strains tested were susceptible to 64 or more jig/ml. Little or no inoculum effect was seen with cefotetan and these strains, whereas it was more marked with piperacillin. Clavulanic acid in concentrations of 0.1, 0.5, and 2 ,ug/ml had no effect upon the activity of cefotetan.
The activity of cefotetan against Staphylococcus aureus was comparable to that of moxalactam and ceftazidime and one-half that of cefoxitin or cefuroxime. Two methicillin-resistant strains were susceptible to .16 ,ug of cefotetan per ml at the higher inoculum.
Eight strains of Lancefield group A Streptococcus pyogenes (not shown in Table 1) were tested, and the mode MIC to cefotetan was 0.25 ,ug/ml (range, 0.25 to 8 jig/ml). The five group D streptococci were not susceptible to cefotetan at 128 ,ug/ml, and the four strains of Streptococcus pneumoniae were all susceptible to 2 pug/ml.
Cefotetan was somewhat less active than the other agents against N. gonorrhoeae. No 13-lactamase producers were included, but those strains which tended to be more resistant to piperacillin were more resistant to cefotetan, although this was not always the case.
In Table 2 are included the susceptibilities of the six known 13-lactamase-producing strains as classified according to Richmond and Sykes (7). It can be seen that the TEM-1 strain was fully sensitive to cefotetan and the other cephalosporins at both inocula but resistant to piperacillin. The strain carrying the chromosomal broadspectrum enzyme Klebsiella Kl was susceptible to cefotetan but not cefuroxime. The two strains containing the group I enzymes were resistant to cefotetan. The protein binding of cefotetan at 50, 200, and 400 ,ug/ml was 87.4, 85.5, and 76.3%, respectively. In Table 3 the effect of serum on the MIC and MBC is shown. Generally there was little or no difference between the MIC and MBC, except for the strains of Proteus mirabilis for which serum had a slight effect on the MIC and MBC. DISCUSSION Cefotetan, a cephamycin derivative (8), exhibits many differences when compared with the widely investigated cephamycin, cefoxitin (1, 9) . It is significantly more active against the Enterobacteriaceae, in which respect it resembles the newer cephalosporins moxalactam (11) and ceftazidime (6). In particular, it is active against the problem organisms of hospital practice, the Serratia, Providencia, and (unlike cefoxitin) many Enterobacter spp. In common with moxalactam and ceftazidime there is less activity against Staphylococcus aureus, and it is possible that increased doses might have to be used when treating an infection caused by this organism. However, there is some information in the case of moxalactam that doses of 3 to 6 g/day are effective in the treatment of staphylococcal sepsis (4).
Cefotetan would appear to be stable to a wide range of r-lactamases. From this study it is not possible to state whether the poor activity against the group I enzymes is due to hydrolysis or poor penetration to the target site; definitive hydrolysis studies would be required to elucidate this point. The poor activity against B. fragilis, cefotetan being markedly less active than cefoxitin, is of interest. Since clavulanic acid did not potentiate cefotetan, as it does other cephalosporins such as cefotaxime (10) , it is suggested that the mechanism of resistance is not related to P-lactamase hydrolysis but rather to poor penetration or lack of affinity of the target site.
Although cefotetan is highly protein bound, it is interesting to note that this binding does decrease when serum concentrations exceed 200 ,ug/ml. It is doubtful if this will have any pharmacological or clinical significance; this contrasts with ceftriaxone which is also highly bound and the excretion of which was possibly affected by the decrease in binding at high serum levels (3). The relatively high binding did not appear to affect adversely the activity in vitro.
Pharmacological studies indicate that cefotetan achieves serum levels about twice those of moxalactam for an equivalent dose. The high protein binding reported here, and in animals by other investigators (5) 
